Skip to main content

Table 5 Neutralization of HIV-1 viruses by anti-V3 mAbs in TZM-bl assay

From: Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors

  anti-V3 mAbs  
# Virus ID Tier Clade 277 903 904 447-52D 1418
1 MW965 1 C 0.34 0.15 <0.1 <0.1 >30
2 DJ263 1 A 8.2 1.7 0.4 <0.1 >30
3 SF162 1 B >30 >30 >30 <0.1 >30
4 JR-CSF 1 B >30 >30 >30 0.3 >30
5 92RW009 1 A >30 >30 >30 >30 >30
6 HIV-001428 2 C >30 15.4 22.8 >30 >30
7 ZM109F.PB4 2 C >30 >30 >30 >30 >30
8 ZM233M.PB6 2 C >30 >30 >30 >30 >30
9 Du156.12 2 C >30 >30 >30 >30 >30
10 JRFL 2 B >30 >30 >30 20 >30
11 RHPA4259.7 2 B >30 >30 >30 >30 >30
  1. The cross neutralizing activities of mAbs generated from Indian patients along with 447-52D (also an anti-V3 antibody), were evaluated against the tier 1 and 2 subtype_A, B, C viruses indicated on the left. The antibodies are shown with antibody IDs (numerical values in bold) at the top of each column. Human anti-parvovirus B19 mAb 1418 was used as negative control. The numerical values in the boxes below are the 50% neutralization titers (IC50) defined as the concentration (μg/ml) of mAb which neutralized 50% of viral infection in the assay. For clarity, this information is coded: IC50 < 1 μg/ml; (Bold), IC50 > 1 μg/ml; (Italic) and >30, where IC50 was not reached. Each experiment was performed at least two independent times.